STOCK TITAN

[Form 4] Ligand Pharmaceuticals Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Metallus Inc. (symbol: MTUS) has filed a Form 144 indicating the proposed sale of 7,500 common shares through Merrill Lynch, Atlanta, on or about July 2, 2025. The filing assigns an aggregate market value of $120,000 to the planned transaction. The shares were originally acquired on March 1, 2024 via a restricted stock unit (RSU) vesting-related compensatory award from Metallus. No other sales by the same insider have occurred in the past three months, and no material, non-public adverse information is asserted in the certification section. With 42,023,268 total shares outstanding, the planned disposition represents roughly 0.018% of the company’s equity, making it immaterial from a dilution perspective but potentially relevant for investors tracking insider sentiment.

Metallus Inc. (simbolo: MTUS) ha presentato un Modulo 144 che indica la proposta vendita di 7.500 azioni ordinarie tramite Merrill Lynch, Atlanta, intorno al 2 luglio 2025. La comunicazione attribuisce un valore di mercato complessivo di 120.000 $ all’operazione pianificata. Le azioni sono state originariamente acquisite il 1 marzo 2024 tramite un premio compensativo legato al vesting di unità azionarie vincolate (RSU) da Metallus. Nessun’altra vendita da parte dello stesso insider è avvenuta negli ultimi tre mesi e nella sezione di certificazione non viene dichiarata alcuna informazione negativa materiale e non pubblica. Con un totale di 42.023.268 azioni in circolazione, la cessione prevista rappresenta circa lo 0,018% del capitale sociale, risultando irrilevante dal punto di vista della diluizione ma potenzialmente significativa per gli investitori che monitorano il sentiment degli insider.

Metallus Inc. (símbolo: MTUS) ha presentado un Formulario 144 indicando la venta propuesta de 7,500 acciones ordinarias a través de Merrill Lynch, Atlanta, alrededor del 2 de julio de 2025. La presentación asigna un valor de mercado agregado de 120,000 $ a la transacción planeada. Las acciones fueron adquiridas originalmente el 1 de marzo de 2024 mediante una concesión compensatoria relacionada con la consolidación de unidades de acciones restringidas (RSU) de Metallus. No se han producido otras ventas por parte del mismo insider en los últimos tres meses y en la sección de certificación no se afirma información adversa material y no pública. Con un total de 42,023,268 acciones en circulación, la disposición planeada representa aproximadamente el 0.018% del capital de la empresa, siendo insignificante desde una perspectiva de dilución pero potencialmente relevante para los inversores que siguen el sentimiento de los insiders.

Metallus Inc. (심볼: MTUS)는 Merrill Lynch, Atlanta를 통해 2025년 7월 2일경 7,500 보통주 매각 예정임을 알리는 Form 144를 제출했습니다. 이번 거래에 대한 총 시장 가치가 120,000 달러로 평가되었습니다. 해당 주식은 2024년 3월 1일 Metallus로부터 받은 제한 주식 단위(RSU) 베스팅 관련 보상으로 처음 취득한 것입니다. 동일 내부자의 최근 3개월 내 다른 매각은 없었으며, 인증 섹션에는 중요한 비공개 부정적 정보가 없습니다. 총 42,023,268 주가 발행된 가운데 이번 매각은 회사 지분의 약 0.018%에 해당하며, 희석 관점에서는 중요하지 않은 수준이지만 내부자 심리를 추적하는 투자자에게는 잠재적으로 의미가 있습니다.

Metallus Inc. (symbole : MTUS) a déposé un Formulaire 144 indiquant la vente proposée de 7 500 actions ordinaires via Merrill Lynch, Atlanta, aux alentours du 2 juillet 2025. Le dépôt attribue une valeur marchande globale de 120 000 $ à la transaction prévue. Les actions ont été initialement acquises le 1er mars 2024 dans le cadre d’une attribution compensatoire liée au vesting d’unités d’actions restreintes (RSU) de Metallus. Aucune autre vente par le même initié n’a eu lieu au cours des trois derniers mois, et aucune information défavorable matérielle et non publique n’est mentionnée dans la section de certification. Avec un total de 42 023 268 actions en circulation, la cession prévue représente environ 0,018% du capital de la société, ce qui est insignifiant du point de vue de la dilution mais potentiellement pertinent pour les investisseurs suivant le sentiment des initiés.

Metallus Inc. (Ticker: MTUS) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 7.500 Stammaktien über Merrill Lynch, Atlanta, etwa am 2. Juli 2025 ankündigt. Die Meldung weist der geplanten Transaktion einen gesamtmarktwert von 120.000 $ zu. Die Aktien wurden ursprünglich am 1. März 2024 im Rahmen einer auf Restricted Stock Unit (RSU)-Vesting basierenden Vergütung von Metallus erworben. In den letzten drei Monaten gab es keine weiteren Verkäufe desselben Insiders, und im Zertifizierungsabschnitt werden keine wesentlichen, nicht öffentlichen negativen Informationen angegeben. Bei insgesamt 42.023.268 ausstehenden Aktien entspricht die geplante Veräußerung etwa 0,018% des Unternehmenskapitals und ist aus Verwässerungssicht unbedeutend, könnte jedoch für Investoren, die das Insider-Sentiment verfolgen, von Interesse sein.

Positive
  • None.
Negative
  • Insider selling: Although small, the proposed disposition of 7,500 shares may be viewed as a modest negative indicator of insider sentiment.

Insights

TL;DR Small insider sale (0.018% of float) via Form 144; negligible dilution, mild negative sentiment signal.

The filing discloses a routine sale of 7,500 Metallus shares, valued at about $120k. Because the shares stem from RSU vesting, the transaction likely reflects personal liquidity or tax planning rather than a strategic statement about the company. The extremely small size versus the 42 million share base means no dilution or liquidity impact. However, insider disposition—especially within 16 months of vesting—can be interpreted as a slight negative indicator of insider confidence, though the scale here does not suggest any substantive concern.

Metallus Inc. (simbolo: MTUS) ha presentato un Modulo 144 che indica la proposta vendita di 7.500 azioni ordinarie tramite Merrill Lynch, Atlanta, intorno al 2 luglio 2025. La comunicazione attribuisce un valore di mercato complessivo di 120.000 $ all’operazione pianificata. Le azioni sono state originariamente acquisite il 1 marzo 2024 tramite un premio compensativo legato al vesting di unità azionarie vincolate (RSU) da Metallus. Nessun’altra vendita da parte dello stesso insider è avvenuta negli ultimi tre mesi e nella sezione di certificazione non viene dichiarata alcuna informazione negativa materiale e non pubblica. Con un totale di 42.023.268 azioni in circolazione, la cessione prevista rappresenta circa lo 0,018% del capitale sociale, risultando irrilevante dal punto di vista della diluizione ma potenzialmente significativa per gli investitori che monitorano il sentiment degli insider.

Metallus Inc. (símbolo: MTUS) ha presentado un Formulario 144 indicando la venta propuesta de 7,500 acciones ordinarias a través de Merrill Lynch, Atlanta, alrededor del 2 de julio de 2025. La presentación asigna un valor de mercado agregado de 120,000 $ a la transacción planeada. Las acciones fueron adquiridas originalmente el 1 de marzo de 2024 mediante una concesión compensatoria relacionada con la consolidación de unidades de acciones restringidas (RSU) de Metallus. No se han producido otras ventas por parte del mismo insider en los últimos tres meses y en la sección de certificación no se afirma información adversa material y no pública. Con un total de 42,023,268 acciones en circulación, la disposición planeada representa aproximadamente el 0.018% del capital de la empresa, siendo insignificante desde una perspectiva de dilución pero potencialmente relevante para los inversores que siguen el sentimiento de los insiders.

Metallus Inc. (심볼: MTUS)는 Merrill Lynch, Atlanta를 통해 2025년 7월 2일경 7,500 보통주 매각 예정임을 알리는 Form 144를 제출했습니다. 이번 거래에 대한 총 시장 가치가 120,000 달러로 평가되었습니다. 해당 주식은 2024년 3월 1일 Metallus로부터 받은 제한 주식 단위(RSU) 베스팅 관련 보상으로 처음 취득한 것입니다. 동일 내부자의 최근 3개월 내 다른 매각은 없었으며, 인증 섹션에는 중요한 비공개 부정적 정보가 없습니다. 총 42,023,268 주가 발행된 가운데 이번 매각은 회사 지분의 약 0.018%에 해당하며, 희석 관점에서는 중요하지 않은 수준이지만 내부자 심리를 추적하는 투자자에게는 잠재적으로 의미가 있습니다.

Metallus Inc. (symbole : MTUS) a déposé un Formulaire 144 indiquant la vente proposée de 7 500 actions ordinaires via Merrill Lynch, Atlanta, aux alentours du 2 juillet 2025. Le dépôt attribue une valeur marchande globale de 120 000 $ à la transaction prévue. Les actions ont été initialement acquises le 1er mars 2024 dans le cadre d’une attribution compensatoire liée au vesting d’unités d’actions restreintes (RSU) de Metallus. Aucune autre vente par le même initié n’a eu lieu au cours des trois derniers mois, et aucune information défavorable matérielle et non publique n’est mentionnée dans la section de certification. Avec un total de 42 023 268 actions en circulation, la cession prévue représente environ 0,018% du capital de la société, ce qui est insignifiant du point de vue de la dilution mais potentiellement pertinent pour les investisseurs suivant le sentiment des initiés.

Metallus Inc. (Ticker: MTUS) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 7.500 Stammaktien über Merrill Lynch, Atlanta, etwa am 2. Juli 2025 ankündigt. Die Meldung weist der geplanten Transaktion einen gesamtmarktwert von 120.000 $ zu. Die Aktien wurden ursprünglich am 1. März 2024 im Rahmen einer auf Restricted Stock Unit (RSU)-Vesting basierenden Vergütung von Metallus erworben. In den letzten drei Monaten gab es keine weiteren Verkäufe desselben Insiders, und im Zertifizierungsabschnitt werden keine wesentlichen, nicht öffentlichen negativen Informationen angegeben. Bei insgesamt 42.023.268 ausstehenden Aktien entspricht die geplante Veräußerung etwa 0,018% des Unternehmenskapitals und ist aus Verwässerungssicht unbedeutend, könnte jedoch für Investoren, die das Insider-Sentiment verfolgen, von Interesse sein.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davis Todd C

(Last) (First) (Middle)
555 HERITAGE DRIVE
SUITE 200

(Street)
JUPITER FL 33458

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 J(1) 233 A $91.0775 161,467 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Metallus (MTUS) shares are being sold under this Form 144?

7,500 common shares are proposed for sale.

What is the total market value of the proposed MTUS share sale?

The aggregate value is $120,000 as stated in the filing.

When were the Metallus shares originally acquired?

The shares vested on March 1, 2024 via a restricted stock unit award.

What percentage of Metallus’s outstanding shares does the sale represent?

Approximately 0.018% of the 42,023,268 shares outstanding.

Which broker will handle the MTUS sale and on what date?

Merrill Lynch, Atlanta, is listed as broker for an approximate sale date of July 2, 2025.
Ligand Pharma

NASDAQ:LGND

LGND Rankings

LGND Latest News

LGND Latest SEC Filings

LGND Stock Data

2.23B
18.83M
2.06%
98.51%
4.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO